This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer ...

Edmund Ingham of Haggerston BioHealth shares his 6-tab due diligence process on Seeking Alpha Premium, covering CRISPR, cash ...

The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to ...

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance ...

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in ...

Biotech picks highlight cystic fibrosis drug trials, rare-disease therapies and upcoming regulatory catalysts as clinical ...

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based ...

The biotech industry has delivered an upbeat performance so far in 2026 despite an uncertain macroeconomic backdrop. Strong ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.

The leading stocks in the KOSDAQ market are rapidly being reshuffled. With the top market cap position changing five times ...